Multicenter evaluation efficacy tolerability safety new first-line antihypertensive drug isradipine Latin-American population Isradipine new antihypertensive dihydropyridine calcium antagonist efficacy tolerability safety ambulatory patients mild-to-moderate hypertension design present study two-week wash-out period confirmation disease weeks active treatment mg isradipine Patients antihypertensive drugs diuretics beta-blockers dose isradipine unchanged study mean decrease mm Hg systolic blood pressure SBP mm Hg diastolic blood pressure DBP Heart rate unchanged difference beats/min mean body weight study patients Isradipine Side effects present treatment period clinical laboratory parameters electrocardiograph intervals unchanged conclusion results isradipine novel drug effective treatment mild hypertension group patients 